|1.||Campos, Francisco: 7 articles (07/2015 - 06/2011)|
|2.||Castillo, José: 7 articles (07/2015 - 06/2011)|
|3.||Sobrino, Tomás: 6 articles (07/2015 - 06/2011)|
|4.||Teichberg, Vivian I: 6 articles (12/2012 - 01/2007)|
|5.||Zlotnik, Alexander: 6 articles (10/2012 - 01/2007)|
|6.||Shapira, Yoram: 6 articles (10/2012 - 01/2007)|
|7.||Blanco, Miguel: 4 articles (10/2013 - 06/2011)|
|8.||Pérez-Mato, María: 4 articles (10/2013 - 06/2011)|
|9.||Gruenbaum, Shaun E: 4 articles (10/2012 - 07/2009)|
|10.||Boyko, Matthew: 4 articles (10/2012 - 11/2011)|
|1.||Body Weight (Weight, Body)
01/01/2002 - "At 96 h post-surgery, the ratio of the weight of the nonligated lobe to body weight was significantly higher in group III than in group I and group II, and induction of the MIB-5 labeling index showed maximum levels in group III. However, quantitative determination of serum glutamic-oxaloacetate transaminase (GOT) showed peak levels in group II at 24 h after surgery. "
02/01/2015 - "In vivo, oral feeding of CCF (100mg and 500mg/kg of body weight) to rats for five consecutive days before a single dose of t-BHP (2mmol/kg, i.p.) showed a significant (p<0.05) protective effect by lowering serum levels of glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate transaminase (GPT). "
04/12/2011 - "YGJ remarkably prevented body weight loss and DMN damage in the liver, and it inhibited the elevation of serum glutamate oxaloacetate transaminase (GOT), and glutamic pyruvic transaminase (GPT). "
07/01/2010 - "Sprague-Dawley rats treated with Dox (15 mg/kg intraperitoneally) showed marked body weight loss, increased abdominal ascites and serum glutamate oxaloacetate transaminase (GOT) level, serum and cardiac lipid peroxidation, myocardial histopathological damage, and depletion of cardiac glutathione (GSH). "
03/01/2003 - "Administration of isoproterenol to mice at a dose of 30 mg/100 g body weight for 3 consecutive days at an interval of 24 h induced lipid peroxidation in cardiac tissue and exhibited a significantly elevated serum glutamate oxaloacetate transaminase (SGOT) level. "
01/01/2014 - "The aim of this study was to analyze the protective effect of an effective dose of oxaloacetate and the human rGOT1 alone and in combination with a non-effective dose of oxaloacetate in an animal model of ischemic stroke. "
01/01/2014 - "In conclusion, our findings indicate that the combination of human rGOT1 with low doses of oxaloacetate seems to be a successful approach for stroke treatment."
02/01/2012 - "Here we review the recent experimental and clinical results where it is demonstrated the potential applicability of oxaloacetate as a novel and powerful neuroprotective treatment against ischemic stroke."
02/01/2012 - "Oxaloacetate: a novel neuroprotective for acute ischemic stroke."
06/01/2011 - "Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study."
|3.||Brain Injuries (Brain Injury)
07/01/2009 - "Treatment with oxaloacetate after traumatic brain injury has been shown to decrease blood glutamate levels and protect against the neurotoxic effects of glutamate on the brain. "
01/01/2012 - "The authors demonstrate that the blood glutamate scavengers oxaloacetate and pyruvate provide neuroprotection after traumatic brain injury, expressed both by reduced neuronal loss in the hippocampus and improved neurologic outcomes. "
11/01/2011 - "In previous studies, we have shown that by increasing the brain-to-blood glutamate efflux upon scavenging blood glutamate with either oxaloacetate or pyruvate, one achieves highly significant neuroprotection particularly in the context of traumatic brain injury. "
01/01/2012 - "Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats."
|4.||Critical Illness (Critically Ill)
06/01/2003 - "While, amino acid mixtures of glutamine dipeptides, ornithine alpha-ketoglutarate, asparagine, oxaloacetate, arginine, aspartate and glutamate have been used in a variety of conditions, prospective randomised controlled trials have not consistently demonstrated improved survival with their use in the critically ill patient. "
|5.||Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
07/01/2012 - "This study investigates the efficacy of blood glutamate scavengers oxaloacetate and pyruvate in the treatment of subarachnoid hemorrhage (SAH) in rats. "
07/01/2012 - "The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage."
|1.||Glutamic Acid (Glutamate)
|2.||Pyruvic Acid (Pyruvate)
|4.||Aspartate Aminotransferases (Aspartate Transaminase)
|5.||Alanine Transaminase (SGPT)
|8.||ruberythric acid (AlP)